Led · Series A · Dec 2018

Omnivore provides a universal POS connectivity platform that enables hundreds of third-party technologies to integrate with diverse POS systems. Led by CEO Mike Wior, the company delivers an end-to-end suite of data-driven solutions that optimize online ordering, pay-at-table, third‑party delivery, kiosk/digital menus, reservations, loyalty, inventory, labor, and analytics. All of these solutions integrate directly into restaurant POS systems to digitize guest and operational experiences. Omnivore raised $10m in a Series A to accelerate development and growth of proprietary products. The company intends to use the funds to minimize friction for restaurant brands, third-party technologies, and POS companies. Its platform targets broad POS interoperability across the restaurant ecosystem.

Participated · Series C · Oct 2017

Attune Medical is a medical device company with a technology platform based on targeted temperature management using the esophageal space. Its flagship product, the single-use ensoETM, is placed in the esophagus like a standard orogastric tube and connects to an external heat-exchange unit to create a closed-loop heat-transfer system. The ensoETM enables efficient core temperature modulation due to proximity to cardiac and great-vessel blood flow, and permits gastric decompression plus administration of fluids and medications while not impeding surgical access. The device is FDA-cleared for use in the esophagus for whole-body temperature management and is used in critical care units, operating rooms, and emergency departments. Attune has supported clinical research for emerging applications, citing the IMPACT study published Nov 17, 2020 in Europace and referencing other work (OPERA) as part of its clinical validation efforts. Financially, the company completed a final closing of a $4M convertible note offering to increase commercial and clinical presence and support further studies; CEO Keith Warner emphasized continued commitment to expanding esophageal-based temperature management applications. Attune Medical develops and sells the EnsoETM, a single-use, fully enclosed esophageal device that modulates core body temperature via lumens connected to an external heat-exchange unit while allowing gastric decompression and enteral access. The EnsoETM can be placed like a standard gastric tube and is cleared for use across operating rooms, recovery rooms, emergency departments, and intensive care units. Attune positions the EnsoETM as the only product cleared for whole-body temperature management in the esophageal environment. The company plans to expand the device’s application into emerging clinical uses such as hypothermia prevention during surgical procedures and to pursue clinical studies and regulatory clearance for applications aimed at reducing esophageal thermal injury from cryo- and radiofrequency-based cardiac ablation. The Series C financing will support continued revenue growth in the global temperature-management market and fund further clinical and regulatory work for new indications. Formerly Advanced Cooling Therapy, the company has received multiple FDA clearances (de novo in 2015 and subsequent 510(k) clearances through 2018), a CE mark in 2014 with later expansions, and licenses for sale in Canada and Australia. Attune Medical develops the EnsoETM, a single‑use, fully enclosed esophageal temperature management device that enables whole‑body warming and cooling via the esophageal environment. The device has two lumens to connect to an external heat‑exchange unit and a third lumen for gastric decompression and drainage, and can be placed similarly to a standard gastric tube. Attune says the EnsoETM is the only product approved for esophageal whole‑body temperature modulation and can be used in the OR, recovery room, emergency room, and ICU. The company holds a US FDA de novo clearance (2015) and multiple 510(k) clearances (2016, 2017), a CE Mark (2014, expanded 2016) and is licensed for sale in Canada and Australia. Attune reports continued adoption by a growing number of major hospitals and that the product requires no additional capital equipment purchase. The company will use recent funding to support continued revenue growth in North America and expansion across key markets worldwide. Advanced Cooling Therapy (ACT) is a Chicago-based emerging medical device firm developing the Esophageal Cooling Device (ECD) to control patient temperature. The ECD is a single-use, fully-enclosed triple-lumen system inserted into the esophagus; two lumens connect to temperature modulation equipment while a third provides gastric decompression and drainage. It can be rapidly inserted by most trained healthcare professionals in a manner similar to a standard gastric tube and is intended for use in the operating room, recovery room, emergency department, and ICU. No other product on the market is approved to use the esophageal environment for whole-body temperature modulation. The device holds a CE mark for sale in Europe and is licensed for sale in Canada; it is currently pending FDA clearance for use in the U.S. ACT closed a $1.5 million Series A to support the full commercial launch of the ECD and to help distribution partners in the EU and Canada. Proceeds will also be used to shepherd the ECD through FDA regulatory approval.